This article is more than 5 years old. Information may no longer be current.
Top intervention news from January: Paclitaxel update, pediatric closure device approved and more
Click Here to Manage Email Alerts
Cardiology Today’s Intervention and Healio Intervention compiled a list of the most-read articles posted in January.
This month, our readers were interested in potential risks of paclitaxel-eluting devices, a study that identified barriers to the pursuit of interventional cardiology by women, a next-generation balloon-expandable transcatheter aortic valve replacement device approved by the FDA and more. Read the full articles below.
First US patient implanted with novel TAVR valve
JC Medical announced that the first U.S. patient was successfully treated with its novel transfemoral transcatheter aortic valve replacement system (J-Valve TF system). The device is designed for patients who require TAVR due to aortic regurgitation. Read more
Resolution of barriers to pursuit of interventional cardiology may improve representation of women
A new study identifies several factors that dissuade female CV fellows-in-training from pursuing interventional cardiology compared with men, including occupational concerns, gender discrimination, job flexibility and overall culture. Read more
Possible mortality risk from paclitaxel-coated devices spurs debate, pauses trials
A meta-analysis finding long-term death risk associated with paclitaxel-coated devices in patients with peripheral artery disease has prompted much debate among vascular interventionalists and caused a temporary halt to enrollment in two ongoing trials. Read more
FDA to investigate potential risks of paclitaxel-eluting devices
The FDA announced it is analyzing data to determine whether there are any long-term risks conferred by paclitaxel-coated products used in patients with peripheral artery disease. In a letter to health care providers, the agency also told clinicians to continue monitoring patients treated with paclitaxel-coated balloons and paclitaxel-eluting stents in accordance with the standard of care, and to discuss with patients with PAD the risks and benefits of all available treatment options. Read more
SCAI: Benefits of paclitaxel-coated devices outweigh risks
Based on current evidence, the benefits of paclitaxel-coated devices for treatment of peripheral artery disease outweigh the risks, but doctors should discuss concerns about mortality risk with their patients, according to a statement issued by the Society for Cardiovascular Angiography and Interventions. Read more
Renal nerve stimulation shows promise for identifying appropriate patients for renal denervation
A first-in-man study shows that renal nerve stimulation appears to be safe and effective along the renal artery and yields large variation in temporary changes in BP per patient and per anatomic location. Read more
FDA approves closure device for patent ductus arteriosus
Abbott announced that the FDA approved its Amplatzer Piccolo occlude closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. Read more
Off-label use of newer P2Y12 inhibitors common in stable ischemic heart disease
More than one-third of patients without ACS who underwent PCI were prescribed prasugrel or ticagrelor between 2009 and 2016, but data are limited on their benefits in stable ischemic heart disease, according to a research letter published in Circulation: Cardiovascular Interventions. Read more
Panel identifies effective exercise programs for PAD
Supervised treadmill exercise therapy has the most evidence for effectiveness in patients with peripheral artery disease, but several other forms of exercise also appear to benefit this population, according to an American Heart Association scientific statement. Read more
Next-generation balloon-expandable TAVR valve receives FDA approval
Edwards Lifesciences announced its next-generation balloon-expandable valve (Sapien 3 Ultra) received approval from the FDA for transcatheter aortic valve replacement in patients with severe, symptomatic aortic stenosis at intermediate or greater risk for open-heart surgery. Read more